Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7613329 | 0.94 | PRKCI (0.48) | PRKCIMAPTNPSR1MAPK1KDM4E | |
| SCHEMBL5130013 | 0.90 | MAPT (0.53) | PRKCIMAPTNPSR1MAPK1KDM4E | |
| SCHEMBL5125323 | 0.89 | MAPT (0.57) | MAPTNPSR1KDM4EBCDIN3DPDE5A | |
| SCHEMBL5128167 | 0.89 | PRKCI (0.50) | PRKCIMAPTNPSR1MAPK1KDM4E | |
| SCHEMBL5123545 | 0.88 | PRKCI (0.64) | PRKCIMAPTNPSR1MAPK1KDM4E | |
| SCHEMBL8179119 | 0.87 | ALDH1A1 (0.45) | MAPK1BCDIN3DPDE5AHSD17B10CYP1A2 | |
| SCHEMBL7519905 | 0.87 | PRKCI (0.58) | PRKCIMAPTNPSR1MAPK1KDM4E | |
| SCHEMBL5120472 | 0.86 | PRKCI (0.48) | PRKCIMAPTNPSR1MAPK1KDM4E | |
| SCHEMBL7514104 | 0.86 | MAPT (0.54) | MAPTNPSR1KDM4EBCDIN3DPDE5A | |
| SCHEMBL5122882 | 0.85 | BCDIN3D (0.41) | PRKCIMAPTNPSR1KDM4EBCDIN3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1685136-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047292-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6133271-A | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
| EP-0920431-A1 | THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006722-A1 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | PRKCI 1513/4885MAPT 2997/4885NPSR1 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.